Shanghai Junshi Biosciences Co Ltd Total Liabilities
Shanghai Junshi Biosciences Co Ltd total liabilities. Based on the latest financial reports, Shanghai Junshi Biosciences Co Ltd (688180) has total liabilities worth CN¥6.16 Billion CNY (≈ $901.19 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shanghai Junshi Biosciences Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shanghai Junshi Biosciences Co Ltd (2014–2025)
Total liabilities of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. This chart illustrates how Shanghai Junshi Biosciences Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Shanghai Junshi Biosciences Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Junshi Biosciences Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $416.30 Million |
|
Zhejiang Yinlun Machinery Co Ltd
SHE:002126
|
China | CN¥12.91 Billion |
|
CMB.TECH NV
BR:CMBT
|
Belgium | €5.82 Billion |
|
Kadant Inc
NYSE:KAI
|
USA | $708.50 Million |
|
GZ Port
SHG:601228
|
China | CN¥29.16 Billion |
|
Kingdee International Software Group Company Limited
F:KDIC
|
Germany | €6.38 Billion |
|
National Health Investors Inc
NYSE:NHI
|
USA | $1.36 Billion |
|
Avicopter PLC
SHG:600038
|
China | CN¥35.62 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Shanghai Junshi Biosciences Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 688180 current and non-current assets.
Liquidity & Leverage Metrics
Shanghai Junshi Biosciences Co Ltd Total Liabilities Ratios Explained
Shanghai Junshi Biosciences Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Junshi Biosciences Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Junshi Biosciences Co Ltd (2014–2025)
The table below shows the annual total liabilities of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.16 Billion ≈ $901.19 Million |
+26.99% |
| 2024-12-31 | CN¥4.85 Billion ≈ $709.68 Million |
+20.57% |
| 2023-12-31 | CN¥4.02 Billion ≈ $588.58 Million |
+44.58% |
| 2022-12-31 | CN¥2.78 Billion ≈ $407.10 Million |
+2.34% |
| 2021-12-31 | CN¥2.72 Billion ≈ $397.81 Million |
+25.30% |
| 2020-12-31 | CN¥2.17 Billion ≈ $317.48 Million |
+51.31% |
| 2019-12-31 | CN¥1.43 Billion ≈ $209.83 Million |
+53.17% |
| 2018-12-31 | CN¥936.18 Million ≈ $136.99 Million |
+832.68% |
| 2017-12-31 | CN¥100.38 Million ≈ $14.69 Million |
+347.80% |
| 2016-12-31 | CN¥22.41 Million ≈ $3.28 Million |
+58.27% |
| 2015-12-31 | CN¥14.16 Million ≈ $2.07 Million |
+8.34% |
| 2014-12-31 | CN¥13.07 Million ≈ $1.91 Million |
-- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more